What is the top stem cell biotech of 2014? Take our poll

What is the most exciting, important, promising, all-around awesome stem cell biotech of 2014? Vote and tell us why in the comments.

9 thoughts on “What is the top stem cell biotech of 2014? Take our poll


  1. Nothing quite like a popularity contest posing as a quality contest.

    Okay, let’s add THE ADULT STEM CELL TECHNOLOGY CENTER, LLC (ASCTC) to this short list of companies known to the author; and they are nearly all publicly-traded companies at that.

    Why vote for ASCTC, besides I own it?

    ASCTC is pursuing development of what’s most needed to knock down the main barriers to effective regenerative cell therapy:

    1. NATURAL adult tissue stem cells produced by the pound for tissue-cell homologous transplantation therapies
    2. Adult tissue stem cell-SPECIFIC biomarkers
    3. Technologies for assaying the positive and negative effects of compounds on adult tissue stem cells, SPECIFICALLY

    No magic. Just science.

    James Sherley, M.D., Ph.D.
    Director, ASCTCLLC


  2. Hi Doc. Thanks for the poll, for all you do to further and educate, and for inviting Doc Lanza to take an ice shower 🙂


  3. It would be good if Paul or one of the other blog authors could provide a summary/commentary paragraph on what each company has done this year? Yes I know I can read the websites of these firms, but it is difficult for a layman to separate the actual scientific breakthroughs and significant 2014 results from the PR hype.


  4. Anticipated peer review publication within the next 2 months will (hopefully) bear the justification for ACT sitting on the top of this little poll. Exciting times indeed. I dare say that ACT may remain top dog for several years to come, considering what’s in the pipeline.

    It was interesting to see a commenter use the term ‘cultists’ referring to those who are confident in ACT.. particularly after reading a WP column that used the exact same term in reference to another Biotech Co which has been hit hard by stock manipulators.

    link : http://www.washingtonpost.com/business/northwest-biotherapeutics-stock-woes-highlight-the-harm-of-short-sales/2014/09/26/78b99b0a-4507-11e4-b47c-f5889e061e5f_story.html

    Just as interesting to look at the recent short sale history of ACT.

    link : http://otcshortreport.com/index.php?index=ACTCD&action=view#.VCjdchYhHZe

    I do hope ACT are smart enough to partner with a large pharma – I don’t think they will be allowed to run on their own. Welcome to our corrupt world – money and politics always trump the advancement of science.

Comments are closed.